MedPath

ONO PHARMACEUTICAL CO

🇯🇵Japan
Ownership
-
Established
1947-01-01
Employees
-
Market Cap
$7.1B
Website
https://www.ono.co.jp/

Clinical Trials

168

Active:40
Completed:82

Trial Phases

4 Phases

Phase 1:43
Phase 2:34
Phase 3:20
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (98 trials with phase data)• Click on a phase to view related trials

Phase 1
43 (43.9%)
Phase 2
34 (34.7%)
Phase 3
20 (20.4%)
Phase 4
1 (1.0%)

ONO-4538 Study in Patients With Richter's Transformation

Phase 2
Recruiting
Conditions
Richter's Transformation
Interventions
First Posted Date
2025-04-20
Last Posted Date
2025-06-04
Lead Sponsor
Ono Pharmaceutical Co. Ltd
Target Recruit Count
14
Registration Number
NCT06936943
Locations
🇯🇵

National Cancer Center Hospital, Chuo Ku, Tokyo, Japan

🇯🇵

Hokkaido University Hospital, Sapporo, Hokkaido, Japan

🇯🇵

Kyusyu University Hospital, Fukuoka, Japan

A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease

Phase 2
Recruiting
Conditions
Alzheimer Disease
Interventions
Drug: Placebo
First Posted Date
2025-03-18
Last Posted Date
2025-06-26
Lead Sponsor
Ono Pharmaceutical Co. Ltd
Target Recruit Count
240
Registration Number
NCT06881836
Locations
🇺🇸

Profound Research LLC at The Neurology Center of Southern California, Carlsbad, California, United States

🇺🇸

Ark Clinical Research, Fountain Valley, California, United States

🇺🇸

Sunwise Clinical Research, Walnut Creek, California, United States

and more 47 locations

A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors

Phase 1
Recruiting
Conditions
NSCLC
Solid Tumor
Interventions
First Posted Date
2025-02-10
Last Posted Date
2025-06-03
Lead Sponsor
Ono Pharmaceutical Co. Ltd
Target Recruit Count
60
Registration Number
NCT06816108
Locations
🇯🇵

National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan

🇯🇵

Osaka International Cancer Institute, Osaka-shi, Osaka, Japan

🇯🇵

The Cancer Institute Hospital Of JFCR, Koto-Ku, Tokyo, Japan

A Study of ONO-1110 in Patients With Social Anxiety Disorder

Phase 2
Recruiting
Conditions
Social Anxiety Disorder (SAD)
Interventions
Drug: Placebo
First Posted Date
2025-02-03
Last Posted Date
2025-06-03
Lead Sponsor
Ono Pharmaceutical Co. Ltd
Target Recruit Count
100
Registration Number
NCT06805565
Locations
🇯🇵

Kokura Mental Clinic, Fukuoka, Japan

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 20
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath